🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Vertex Pharmaceuticals Incorporated VRTX NDXSPXR3KPHARMA

Healthcare · Biotechnology · United States
https://www.vrtx.com
Company Profile ↓
$535.17
+35.17% 1Y
Mkt Cap$135.56B
P/E31.13
P/B6.36
52W High$557.96
52W Low$376.62
Book Value$79.92
EPS (TTM)$17.19

Company Overview

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 20.9%.

Steady Revenue Expansion

Revenue has grown at a 10.4% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 35.0%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.10.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $12.00B (+8.9% YoY); net profit $3.95B.
  • Trailing 12 Months Year-on-year growth — revenue +12.5%, earnings +8.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 10.4%, profit CAGR 6.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:10.35%
1 Year:12.50%

Compounded Profit Growth

5 Years:5.97%
1 Year:8.00%

Stock Price Performance

1 Year:+35.17%
6 Months:+23.00%
3 Months:+12.11%
1 Month:+3.65%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 87% of range
$376.62 $557.96
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.53 · Neutral
Price Performance
1M+3.65%
3M+12.11%
6M+23.00%
1Y+35.17%
Valuation vs Sector

P/E of 31.13 is above the sector median of 25.61 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 23.5%.
  • Healthy ROCE of 20.9%.
  • Excellent profit margin of 35.0%.
  • Compounding revenue at 10.4% over 5 years.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
31.13
Industry PE
25.61
Forward P/E
26.58
PEG Ratio
1.89
Book Value
$79.92
Price to Book
6.36
P/S
10.23
EV/EBITDA
24.10
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
10.35%
Profit 5Y
5.97%
Revenue (YoY)
12.50%
Earnings (YoY)
8.00%

Profitability & Returns

ROCE
20.91%
ROE
23.54%
ROA
11.93%
Profit Margin
35.00%
Op Margin
38.05%
Gross Margin
54.96%
EPS (Latest Qtr)
$4.31
EPS (TTM)
$17.19

Balance Sheet & Liquidity

Debt/Equity
0.10
Quick Ratio
2.54
Current Ratio
3.19
Debt
$1.98B
Total Assets
$27.42B
Current Assets
$11.73B
Working Capital
$7.34B

Ownership

Promoter Holding
0.21%
Chg in Prom Hold
0.00%
FII / Inst Holding
98.00%
Chg in FII Hold
0.03%

Financial Snapshot

Enterprise Value
$135.56B
Total Revenue (TTM)
$12.59B
EBITDA
$5.10B
Free Cash Flow
$2.63B
Operating Cash Flow
$4.29B
Shares Outstanding
253.30M
Gross Margin
54.96%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VRTX Vertex Pharmaceuticals Incorporated NDXSPXR3KPHARMA 535.17 31.13 $135.56B 0.00% 20.91% 23.54% 10.35% 5.97%
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,306.69 43.95 $1.16T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 267.61 31.05 $644.91B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 285.19 80.56 $503.96B 2.54% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 424.98 27.29 $381.46B 2.47% 9.74% 14.15% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPXR3KPHARMA 147.24 117.79 $363.27B 2.31% - 6.96% 5.64% 10.01%
7 NVS Novartis AG PHARMA 156.27 23.61 $297.02B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 172.57 25.80 $267.64B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 676.54 36.45 $250.15B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -----714.72M544.13M578.16M651.63M640.80M752.16M784.53M870.11M858.43M941.29M949.83M1.41B1.52B1.52B1.54B1.63B1.72B1.79B1.98B2.10B2.20B2.33B2.37B2.49B2.48B2.69B2.65B2.77B-2.77B2.96B3.08B3.19B2.99B3.33B
Cost of Revenue ----------------------------------363.00M407.50M414.80M466.00M392.80M-
Gross Profit ----------------------------------2.41B2.56B2.66B2.72B2.59B-
Operating Expenses ----------------------------------1.38B1.40B1.42B1.59B1.46B-
Operating Income -53.70M-14.33M3.35M-18.73M39.64M270.84M52.71M-326.04M125.74M128.90M172.88M205.65M127.72M276.81M269.96M99.33M551.47M720.22M718.03M672.24M745.79M887.80M-37.90M1.05B1.04B1.11B1.13B779.00M1.03B1.04B1.14B-3.51B1.12B-1.03B1.15B1.24B1.13B1.14B1.25B
EBITDA ----------------------------------1.08B1.34B1.36B1.39B1.19B-
Interest Expense ---------------------------------2.80M3.00M3.70M3.30M3.30M--
Pretax Income ----------------------------------730.40M1.28B1.30B1.33B1.25B-
Tax Provision ----------------------------------84.10M250.10M215.90M139.90M221.50M-
Net Income -73.73M-41.63M-64.53M-38.84M32.95M247.76M18.00M-102.95M100.68M210.26M207.36M128.75M1.55B268.63M267.43M57.52M583.23M602.75M837.27M667.43M604.19M653.10M67.00M851.90M762.10M810.50M930.50M699.80M915.70M1.04B1.10B-3.59B1.05B-646.30M1.03B1.08B1.19B1.03B1.10B
Diluted EPS --0.17-0.26-0.160.130.990.07-0.410.390.810.800.505.971.031.030.222.232.293.182.532.302.490.263.282.963.133.592.693.523.974.21-13.924.01-2.493.994.204.654.024.31
R&D Expense 310.18M255.86M271.01M272.37M248.45M273.56M289.45M454.95M306.66M310.55M337.53M330.51M437.88M339.49M379.09M555.95M480.01M448.53M420.93M493.50M466.58M456.00M1.41B493.75M603.10M---------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 175.50M101.89M143.37M1.41B1.53B1.21B580.41M1.03B1.70B2.49B3.05B4.16B6.21B-8.93B9.87B11.02B12.00B
Cost of Revenue --------------1.08B1.26B1.53B1.65B
Gross Profit --------------7.85B8.61B9.49B10.35B
Operating Expenses --------------3.60B4.83B9.72B5.80B
Operating Income -462.71M-614.01M-696.08M113.82M46.73M-610.01M-692.41M-466.88M9.94M123.24M635.15M1.20B2.86B-4.25B3.78B-233.40M4.55B
EBITDA --------------4.44B4.61B486.30M4.87B
Interest Expense --------------54.80M44.10M30.60M13.30M
Pretax Income --------------4.23B4.38B248.50M4.64B
Tax Provision --------------910.40M760.20M784.10M690.00M
Net Income --642.18M-754.63M29.57M-107.03M-445.03M-738.55M-556.33M-112.05M263.48M2.10B1.18B2.71B-3.32B3.62B-535.60M3.95B
Diluted EPS -3.27-3.71-3.770.14-0.50-1.98-3.14-2.31-0.461.048.094.5110.29-12.8213.89-2.0815.32
R&D Expense 516.91M550.27M637.42M707.71M765.90M882.10M855.51M995.92M1.05B1.32B1.42B1.75B1.83B3.05B----

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jan 2018Dec 2018Jan 2019Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --1.96B1.73B2.20B2.76B2.32B2.33B2.50B2.90B3.55B3.56B6.25B6.26B8.32B11.75B13.43B18.15B22.73B22.53B25.64B
Current Assets -----------------13.23B14.14B9.60B11.20B
Cash & Equivalents 355.66M389.12M446.66M243.20M475.32M489.41M569.30M625.26M714.77M1.18B1.67B-2.65B-3.11B5.99B6.79B10.50B10.37B4.57B5.08B
Inventory -----------------460.60M738.80M1.21B1.69B
Receivables -----------------1.44B1.56B1.61B2.05B
Total Liabilities --859.14M1.22B1.24B1.52B962.64M1.24B1.40B1.56B1.50B-1.81B-2.23B3.06B3.33B4.24B5.15B6.12B6.98B
Current Liabilities --284.88M474.78M392.35M432.62M397.83M368.25M506.17M792.54M807.26M-1.12B-1.33B1.88B2.14B2.74B3.55B3.56B3.86B
Long Term Debt ---------------------
Total Debt -----------------899.70M808.40M1.74B2.03B
Total Equity 271.30M238.87M1.10B503.97M786.84M999.18M1.36B1.08B939.97M1.16B2.03B-4.44B-6.09B8.69B10.10B13.91B17.58B16.41B18.67B
Shares Outstanding -----------------257.01M257.70M256.94M253.99M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -226.48M-427.59M-635.44M143.74M267.84M-60.67M-573.11M-365.43M236.10M844.94M1.27B1.57B3.25B-4.13B3.54B-492.60M3.63B
Investing Cash Flow -360.65M-508.73M7.30M----268.86M51.24M-483.33M-202.16M-1.24B99.40M--321.10M-3.14B-3.77B-945.40M
Financing Cash Flow 620.74M999.01M425.06M----188.92M133.27M68.40M-71.22M126.80M-505.30M--67.70M-562.20M-1.49B-2.26B
Capital Expenditure -32.18M-23.50M-38.05M-34.59M-71.14M-51.39M-51.20M-45.30M-56.56M-99.42M-95.45M-75.40M-259.80M--204.70M-258.40M-485.40M-437.60M
Free Cash Flow -258.66M-451.08M-673.50M109.14M196.70M-112.06M-624.31M-410.73M179.54M745.52M1.17B1.49B2.99B-3.93B3.28B-978.00M3.19B
Net Change in Cash --------------3.74B-166.60M-5.76B424.70M
Share Buybacks --------00350.04M186.00M539.10M1.43B0427.60M1.18B2.02B

Ratios (Annual)

Figures in %.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------87.9%87.2%86.1%86.2%
Operating Margin % -263.6%-602.6%-485.5%8.1%3.1%-50.3%-119.3%-45.2%0.6%5.0%20.8%28.8%46.0%-47.6%38.3%-2.1%37.9%
Net Margin % --630.3%-526.3%2.1%-7.0%-36.7%-127.2%-53.9%-6.6%10.6%68.8%28.3%43.7%-37.2%36.7%-4.9%32.9%
ROE % --58.6%-149.7%3.8%-10.7%-32.8%-68.7%-59.2%-9.7%13.0%47.3%19.3%31.2%-23.9%20.6%-3.3%21.2%
ROCE % --36.8%-55.7%6.3%2.0%-31.8%-35.2%-23.4%0.5%4.5%12.4%17.1%28.9%-27.6%19.7%-1.2%20.9%

Shareholding Pattern

Insiders
0.21%
Institutions
98.00%
Public Float
98.21%

Top Institutional Holders

#Holder% HeldSharesValue
1 Capital World Investors 10.29% 26.12M $13.32B
2 Blackrock Inc. 9.50% 24.11M $12.30B
3 Capital Research Global Investors 7.68% 19.49M $9.94B
4 Vanguard Capital Management LLC 6.53% 16.58M $8.46B
5 State Street Corporation 4.68% 11.87M $6.06B
6 Invesco Ltd. 3.17% 8.04M $4.10B
7 JPMORGAN CHASE & CO 2.57% 6.52M $3.32B
8 Geode Capital Management, LLC 2.37% 6.02M $3.07B
9 Vanguard Portfolio Management LLC 1.92% 4.88M $2.49B
10 Capital International Investors 1.85% 4.70M $2.39B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VRTX

Google News ue, 20 Oct 2026

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUFgyYVJvNnAxN1I1bmZmcnZIQXIzVC1uNlZGUzZqR3ozSEEtYnV3T1p4ZG1TRGRhRUhRY1NJZllOUzBqTjVRUmdNelBKMV9BZ1dtcUk2bng3NlJFdjlEV0ZIUEg2TVFuZUNJZHFCQXRmNFVza2FidlZOLXZhbEFlM3QyY2pMNTJKLVJ5Z3…

Google News hu, 22 Oct 2026

Vertex (VRTX) Stock Could Be 32% Undervalued Despite New ALYFTREK Data - Simply Wall Street

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxPRVBqa2FOdFJKbHM2Q0JBSzRqckRRbW0zTm85SHdMRGJpNk9wdEQ1YVhFUDhpSW94bmhpVGM2a1dUOVlYRE96OWlwWW1hU3ZzeG5jc0pVZzVHekhwQ2UzbEpHaUdobGk5ZkIweDVjOTVZRDZ5d1lKV2Y5RUFyQlBZQjVtcEZSdWUtNnk3bW…

Google News Wed, 21 Oct 2026

Why Should You Think About Vertex Differently Now? - Trefis

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNeGs1WnJDZHk3LUJ1VGk2ckhPUi0xQlJDREVLZzl6WE9PdHdPbFR6Q0t4LU9VRzBrWVdSV1k3VUpHMjNoNnViNjdpSzhXdjNsX01zUnEwVGtTTmVYdlhRQ05aWHhadHhiMzY3QTkxd3FLaEpFcE9STDVPQjVSeXk1enlMY1ZEanlqWWh3OX…

Google News hu, 01 Oct 2026

Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.21% on Oct 1: What Investors Need To Know - TradingKey

<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQUVBvRU5Ka3lybzlFREp2T2ZtSGJfOXBydTNKU3BQYTNjaTAyTjZudWk1NEwzOFcwY0l3ejlPbjBYUExiM0c2bWROUG1WaHpoNnBiUUwxVU9zcGZXZE5Cc3BKQml1RUVmS1U4d011czNPWjR5SW9RVHhtWDRkWkg0VmdWcmgzbUtPdl93?o…

Google News Sat, 17 Oct 2026

Vertex (VRTX) Stock May Be 35% Undervalued Despite New ALYFTREK Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPeUhGcExoU1FjUzYwTzMwcUNfTm8xcXJBR1BIQkh4ZWxBenR0OHZONFZyOXQyak9hazdsRlZVODRWemxPcVUybXJvNWFLc1NhS2xlUmhOV1JrUE5rWW9ZSktPa3lQNkJFWFI5OFZpQWNPc0NSdVhHdjhBd2JYN29JMm5UNFFpWHB3aUg3OE…

Google News hu, 22 Oct 2026

VRTX Nov 2026 520.000 put (VRTX261127P00520000) Interactive Stock Chart - Yahoo! Finance Canada

<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTFA5MGNzMS1HUUVXRGxMUmtmQzlGQVNsa0JxNTY3WWc1Zmk5QnV3QW5iWUxXb3ZIdzJlLUlLb0hXTjkxNG4tV0d1RnNxTFJtQnZKckU0RmRKZExNeU9sV0NxU3NnQnhsZUZ2M1FQSzlB?oc=5" target="_blank">VRTX Nov 2026 520.0…

VRTX — Frequently Asked Questions

What is the current share price of Vertex Pharmaceuticals Incorporated (VRTX)?

As of 2026-10-22 16:30 PDT, Vertex Pharmaceuticals Incorporated (VRTX) trades at $535.17 on NasdaqGS. Its 52-week range is $376.62 to $557.96.

What is the market capitalisation of VRTX?

Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalisation of $135.56B on NasdaqGS.

What is the P/E ratio of VRTX?

VRTX trades at a trailing price-to-earnings (P/E) ratio of 31.13. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 6.36.

What is the return on equity (ROE) of VRTX?

VRTX has a return on equity (ROE) of 23.54%. Its return on capital employed (ROCE) is 20.91%.

Is VRTX a good stock to buy?

This page provides a data-driven analysis of Vertex Pharmaceuticals Incorporated (VRTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space